Reviews/Psoriasis Psoriatic Arthritis/Bimekizumab ACR50 in biologic-naive psoriatic arthritis
Psa PJT · PSA-PJT-05 · v2
One large, carefully run trial in patients who had never taken a biologic drug tested bimekizumab against a dummy treatment [1]. At four months, far more patients on bimekizumab reached the target level of joint improvement than those on placebo (44% versus 10%) [1], and the same trial's later read-outs confirmed the early result [4] and showed it holding up through one year [3] and two years [5]. The gap between drug and placebo was so large and so statistically clear that ordinary sources of error cannot explain it. The main limitation is that this placebo comparison comes from just one study, with the other papers being follow-ups of the same trial rather than separate confirmations. The panel treated the finding as well established while noting that dependence on a single trial keeps it from being beyond all question.
A single phase 3 placebo-controlled RCT in biologic-naive PsA [1] reports week-16 ACR50 of 44% for bimekizumab versus 10% for placebo (odds ratio 7.1, p<0.0001), with adalimumab as an active reference at 46% [1]. The same trial's 24-week readout restates the comparison as 43.9% versus 10.0%, p<0.001 [4]. Responses were sustained to week 52 [3] and, at 2 years, 79.4% of bDMARD-naive week-16 responders maintained ACR50 [5]. The corpus contains no second, independent placebo-controlled trial in this population. The contested point: The evidence does not divide on whether the effect exists but on how much it rests on one study. The placebo comparison comes solely from BE OPTIMAL, and [3], [4], [5] and [8] are extensions or re-reports of that same trial rather than independent replications.
All 8 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Psoriasis Psoriatic Arthritis, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The placebo comparison in biologic-naive patients derives from a single trial (BE OPTIMAL); papers [3], [4], [5] and [8] are extensions or re-reports of that same study, so there is no independent trial replication.
The placebo comparison exists only at week 16; later timepoints [3][5][8] have no placebo arm, so unqualified 'superior to placebo' is strictly a week-16 (primary endpoint) statement.
Where it remains uncertain. The placebo comparison derives from a single trial measured only at week 16; [3], [4], [5] and [8] are extensions of that same study with no independent replication and no later placebo arm.
Aleatory
The 44% versus 10% contrast [1] is a single trial's estimate; random patient-level variation is bounded only by that study's size (431 bimekizumab / 281 placebo) [1].
The load-bearing papers from a corpus of 8, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Primary placebo-controlled evidence in the exact biologic-naive population
“At week 16, significantly more patients receiving bimekizumab (189 [44%] of 431) reached ACR50 response versus placebo (28 [10%] of 281; odds ratio 7.1, p<0.0001; adalimumab 64 [46%] of 140).”
Panel auditInternal validity: high · scope of inference: Biologic-naive patients with active psoriatic arthritis at week 16.Key limitations: single 16-week timepoint for primary contrast · abstract gives no confidence interval
Durability of ACR50 to 52 weeks in the same population
“ACR20/50/70, PASI75/90/100 and MDA responses were sustained with bimekizumab to Week 52, consistent with results at Week 16.”
Panel auditInternal validity: not assessable from abstract · scope of inference: Biologic DMARD-naive psoriatic arthritis patients over 52 weeks of bimekizumab.Key limitations: no placebo contrast at 52 weeks · no numbers or sample size in abstract
Confirms the Wk16 placebo comparison and primary endpoint attainment
“Primary endpoint met (Wk 16 ACR50: 43.9% BKZ vs 10.0% PBO, p<0.001; ADA: 45.7%).”
Panel auditInternal validity: high · scope of inference: Biologic DMARD-naive psoriatic arthritis patients at weeks 16–24.Key limitations: sample size not stated in abstract · no confidence interval given
The abstract describes high proportions sustaining ACR50 among week-16 responders but reports no placebo comparator to determine direction versus placebo.
Panel auditInternal validity: not assessable from abstract · scope of inference: Biologic DMARD-naive psoriatic arthritis patients who responded at week 16, followed to week 52.Key limitations: responder-enriched subgroup · no placebo contrast
4 of 8 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A large, well-conducted, adalimumab-referenced placebo-controlled RCT in the exact population carries the claim decisively, capped just below the ceiling because the placebo evidence rests on a single trial.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No independent replication of the placebo comparison. All placebo evidence traces to BE OPTIMAL [1]; [3][4][5][8] are its extensions, so the effect has not been reproduced in a separate trial. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A second, independently conducted placebo-controlled phase 3 RCT of bimekizumab in biologic-naive active PsA reporting week-16 ACR50.
Open question: Would an independent placebo-controlled trial reproduce the week-16 ACR50 superiority seen in BE OPTIMAL? Why it is still open: The corpus contains only one placebo-controlled trial in biologic-naive PsA [1], with all other papers being its extensions [3][4][5][8].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19